GeneSights Jewish Genetics Online Learning Series Unveils “Lesson” on Inflammatory Bowel Disease (IBD)

July 31, 2013

Crohn’s Disease and Ulcerative Colitis More Common Amongst Ashkenazi Jews

New York, New York (PRWEB) July 31, 2013

Individuals seeking to learn about Crohn’s disease and ulcerative colitis (collectively known as inflammatory bowel disease, or IBD) can self-educate at GeneSights, the free online education resource presented by the Program for Jewish Genetic Health of Yeshiva University/Albert Einstein College of Medicine. IBD affects more than 1.4 million Americans and its prevalence is significantly higher in individuals of Ashkenazi Jewish descent as compared to the general population.

GeneSights consists of individual “lessons” with topics selected based on their current relevance to the Jewish community, including specific diseases and medical conditions, genetic technologies, and bioethical issues, and answers the question, “What does the mean for me because I am Jewish?”

The GeneSights IBD lesson, co-sponsored by the Crohn’s & Colitis Foundation of America- Greater New York Chapter, features expert lecturer Dr. Judy Cho, a Professor at Yale University and the director of the Yale Inflammatory Bowel Disease Program. The new IBD lesson is accompanied by a 2-minute public service announcement video that features a real patient story.

Visitors viewing the full lesson on IBD will:

  •     Learn about the symptoms of, and differences between, Crohn’s disease and ulcerative colitis
  •     Gain an understanding of the Jewish genetic aspect of IBD
  •     Discover how family history can help one assess his or her risk for IBD
  •     Explore the different management strategies, treatments, research studies and support groups that are available for those with IBD

“People are largely unaware that Crohn’s disease and ulcerative colitis affect Jews disproportionately,” said Nicole Schreiber-Agus, PhD, program director for the Program for Jewish Genetic Health and a member of the GeneSights production team. “Similar to our inaugural lesson on hereditary breast and ovarian cancer, GeneSights provides a centralized location to help the Jewish community understand their genetic risk for Crohn’s and colitis, as well as identify the symptoms, treatment options and other available resources for managing their illnesses.”

Launched in May 2013, GeneSights is designed to provide effective and accessible learning at the viewers’ convenience and to encourage these viewers to become active in ensuring their own health and well being. Besides the new lesson on IBD, the site also currently features a lesson on hereditary breast and ovarian cancer, and a two-part “Genetics 101” webinar to serve as a genetics overview for the typical viewer who may desire a baseline lesson. New lessons will appear on GeneSights approximately every two months.

Seed funding for the GeneSights series was provided in part by UJA-Federation of New York and by a generous grant in honor of Beatrice Milberg. For more information, visit http://www.genesights.com/about/

The Program for Jewish Genetic Health, a joint initiative between Yeshiva University and the Albert Einstein College of Medicine, was established with the goal that nobody in the Jewish community facing a genetic health issue should be deprived of proper care due to lack of awareness, financial barriers or difficulty in navigating the healthcare system. For more information, visit http://www.yu.edu/genetichealth.

The Crohn’s & Colitis Foundation of America’s (CCFA) mission is to cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundation works to fulfill its mission by funding research, providing educational resources for patients and their families, medical professionals, and the public, and furnishing supportive services for those afflicted with IBD. For more information, visit http://www.ccfa.org.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10976422.htm

Source: prweb

comments powered by Disqus